You are here
- Home
- Therapy Areas
- Neuroscience
A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for major depressive disorder
- Disease
- depressive disorder
- Drug Name
- AZD6765
- Generic Name
- AZD6765
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- I
- Start Date
- Dec 14, 2009
- Study Name
- D2285C00001
- Study Id
- D2285C00001
- ClinicalTrials.gov ID
- NCT01046630
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
